Abstract. Background: Myeloablative high-dose chemotherapy (HDT) followed by single autologous stem cell transplantation is currently the standard treatment for patients younger than 65 years with newly diagnosed multiple myeloma (MM). Several randomized controlled trials (RCTs) comparing HDT with standard dose therapy (SDT) have shown some benefit in overall survival (OS) and progression-free survival (PFS), whereas other RCTs did not confirm this finding. In this study we attempted to analyze the current data in terms of the endpoints OS and PFS. Materials and Methods: We searched PubMed, Embase, the registry of abstracts of former meetings of the American Society of Hematology (ASH), as well as the registry of clinical trials provided by the U.S. National Ministries of Health, ClinicalTrials.gov. The search included the terms ‘myeloma’ combined with ‘transplant’ or ‘high-dose’ or ‘myeloablative’. The search was restricted to RCTs. Furthermore, we searched bibliographies of included trials and recent reviews (1, 11), the meta-analysis of Koreth et al. (10) and one older meta-analysis (12) to find further relevant RCTs. Amongst the 3,484 results we found nine RCTs that met the inclusion criteria given below, but no RCTs additional to the ones of Koreth et al.

Correspondence to: Wolfram C.M. Dempke, MD, Ph.D., MBA, Medical Oncology, Industriestrasse 41, D-81245 Munich, Germany. Tel: +49 8937912632, Fax: +49 8937912633, e-mail: wolfram.dempke@web.de

Key Words: Myeloma, transplantation, stem cell, meta-analysis, myeloablative high-dose chemotherapy.

Multiple myeloma (MM) is a malignant disease of plasma cells accumulating in the bone marrow, which produce immunoglobulin or immunoglobulin light chains. The main symptoms are osteolysis, renal insufficiency, anaemia and infection. At diagnosis, they may vary from changes of the blood count to severe bone lesions of the spinal cord. In most cases, the disease is diagnosed between the ages of 65 and 70 years. MM is one of the most common haematological disorders and has had a poor prognosis for many decades (1). In recent years the introduction of novel agents like thalidomide, lenalidomide and bortezomib has led to some improvement in overall survival (OS) and progression-free survival (PFS). Myeloablative high-dose chemotherapy (HDT) followed by single autologous stem cell transplantation is currently the standard treatment for patients younger than 65 years with newly diagnosed MM (2) and is recommended by the National Comprehensive Cancer Network (NCCN) (3). Several randomized controlled trials (RCTs) (4-6) comparing HDT with standard-dose therapy (SDT) have shown some benefit in OS and PFS, whereas other RCTs did not confirm this finding (7-9). Koreth et al. (10) performed a meta-analysis summarizing the existing data of the RCTs including 2,411 patients. These authors found a significant superiority for HDT in PFS but not in OS. Since new data have been published recently, we attempted to re-analyze the current data in terms of the endpoints OS and PFS.

Materials and Methods

Data sources. We analyzed PubMed, Embase, the registry of abstracts of former meetings of the American Society of Hematology (ASH), as well as the registry of clinical trials provided by the U.S. National Ministries of Health, ClinicalTrials.gov. The search included the terms ‘myeloma’ combined with ‘transplant’ or ‘high-dose’ or ‘myeloablative’. The search was restricted to RCTs. Furthermore, we searched bibliographies of included trials and recent reviews (1, 11), the meta-analysis of Koreth et al. (10) and one older meta-analysis (12) to find further relevant RCTs. Amongst the 3,484 results we found nine RCTs that met the inclusion criteria given below, but no RCTs additional to the ones of Koreth et al.
Inclusion criteria. Studies were required to be prospective randomized trials with a control arm and to have compared high-dose chemotherapy (HDT) including autologous bone marrow transplantation with standard-dose chemotherapy (SDT). In the HDT arm, any kind of myeloablative therapy was accepted. As common during the time, trials using total body irradiation (TBI) in the HDT arm were also accepted. Inclusion was restricted to studies recruiting only newly diagnosed patients with untreated multiple myeloma. Hazard ratios (HRs) of OS and PFS, or data to calculate them had to be provided.

Data extraction. Data extracted from the trials are summarized in Tables I-III. We collected data on: name of first author, start of enrollment, number of participants and therapy in both arms and entry criteria. We also listed characteristics of the patients included: median age, beta-2-microglobulin and, as reported, either Durie-Salmon stage (13) or stage according to the International Staging System (14). In terms of the results, we extracted effects on OS and PFS, as well as the rate of treatment-related mortality (TRM) and complete remission (CR). To evaluate the quality of studies, we analysed their power, the fraction of patients receiving off-protocol salvage therapy, the duration of follow-up, the countries of included centres and rate of drop-out after randomisation. Following the example of Koreth et al., we adhered to common guidelines for quality control in meta-analysis (15).

Data analysis. Data analysis was performed using the open source programming software R (see the Comprehensive R Archive Network (CRAN) at http://cran.R-project.org). The HRs with 95% confidence intervals (CI) of all studies for OS and PFS were illustrated by a forest plot. In calculating the combined HRs, the random effects model was applied. Three subgroup analyses with the application of one of the following exclusion criteria were carried out: studies with less than four years follow-up (excluded in ‘long follow up’), non-standard studies (explained below), studies using the application of TBI. We wanted to investigate this last subgroup because a randomised controlled trial by Moreau et al. showed benefit for treatment of HDT without TBI compared to HDT combined with TBI (16). Furthermore, we examined statistical heterogeneity with the Q statistic and judged publication bias by a funnel plot (17).

Results

Included trials. In our search, we found 3,484 results. After title/abstract review, we considered 3,321 publications to be definitely irrelevant. Amongst the remaining 163 studies, we found 9 RCTs that met all inclusion criteria. The main reasons for exclusion were: non-RCT, lack of one arm, or addressing different questions other than HDT vs. SDT. The following RCTs met inclusion criteria but were excluded in a subgroup-analysis, because they were considered as ‘non-standard’: The MAG 90 trial (18) was excluded for including a per-protocol rescue treatment with HDT and stem cell transplantation for the standard arm. Patients in this arm started with a different induction regimen (VMCP: vincristine, melphalan, cyclophosphamide and prednisone vs. VAMP: vincristine, doxorubicine, methylprednisolone) and were treated like the high-dose arm at the time of disease progression. The trial was accepted because stem cell transplantation was only a rescue-treatment, in part also used in other trials. The HOVON 24 trial

### Table I. Study design.

<table>
<thead>
<tr>
<th>Study (Author)</th>
<th>Power</th>
<th>Follow-up (months)</th>
<th>No. of centers</th>
<th>Country</th>
<th>Randomization</th>
<th>Dropout after randomization</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFM90 (Attal)</td>
<td>80% to detect if probability of 5-year OS was 50% (HDT) vs. 10% (SDT)</td>
<td>SDT: 37 vs. HDT: 41</td>
<td>33</td>
<td>France, Belgium</td>
<td>Upfront</td>
<td>0% 26%</td>
</tr>
<tr>
<td>MAG90 (Fermand)</td>
<td>80% to detect a 20% mortality reduction with early HDT compared with late HDT (HR 0.60) vs. SDT</td>
<td>58</td>
<td>14</td>
<td>France</td>
<td>Upfront</td>
<td>0% 2%</td>
</tr>
<tr>
<td>MAG91 (Fermand)</td>
<td>80% to detect OS benefit with HDT (710 patients)</td>
<td>120</td>
<td>14</td>
<td>New Zealand</td>
<td>Upfront</td>
<td>0% 24%</td>
</tr>
<tr>
<td>MRC7 (Child)</td>
<td>80% to detect a 10% OS improvement with HDT (100 patients)</td>
<td>SDT: 32 vs. HDT: 40</td>
<td>83</td>
<td>USA</td>
<td>After induction</td>
<td>&lt;1% 1%</td>
</tr>
<tr>
<td>S9321 (Barlogie)</td>
<td>81% to detect a survival improvement of 33% with early HDT compared with late HDT (HR 0.60) vs. SDT</td>
<td>76</td>
<td>64</td>
<td>New Zealand</td>
<td>After induction</td>
<td>&lt;1% 1%</td>
</tr>
<tr>
<td>PETHEMA (Bladé)</td>
<td>80% to detect an increase in 2-year EFS from 40% to 55%</td>
<td>M97G (Palumbo)</td>
<td>To detect a statistically significant increase of 20% in EFS at 2 years (240 patients)</td>
<td>SDT: 39 vs. HDT: 41</td>
<td>52</td>
<td>73</td>
</tr>
</tbody>
</table>

EFS: Event-free survival; HDT: high-dose therapy; SDT: standard-dose therapy; HR: hazard ratio; NR: not reported; OS: overall survival.
used a relatively aggressive induction regime for both arms (VAD: vincristine, doxorubicine, dexamethasone followed by cyclophosphamide followed by melphalan 70 mg/m² allocated twice at six-to-eight-weeks intervals). Myeloablative treatment in the HDT arm was cyclophosphamide + TBI. This treatment might have had an impact on outcomes such as the need for rescue treatment in the SDT arm. M97G (6) focused on patients ineligible for standard stem cell transplantation treatment. Therefore, patients were older (up to 70 years) and a reduced dose of melphalan 100 mg/m² allocated twice at two-month intervals (Mel 100 ×2) at each time followed by stem cell transplantation (tandem transplant) was scheduled. Furthermore, the two arms received different induction regimens as that was state of the art at the start of the trial. As the total dose of melphalan was similar to that of other trials, we included the study in the initial analysis. Another ‘intermediate-dose’ trial was IFM 99-06 (20): patients enrolled were ineligible for regular HDT regimen and aged between 65 and 75 years. The HDT arm used melphalan 100 mg/m² allocated twice at two-month intervals (Mel100 ×2) and there were two standard arms (MPT: melphalan, prednisone, thalidomide vs. MP: melphalan, prednisone). As we did not consider it as clinically meaningful to combine the two standard arms (21), we calculated outcomes separately. As a standard of analyses, Mel100×2 vs. MPT was considered. Using the MP arm instead did not result in clinically relevant difference in combined HRs. Hazard estimates for OS ranged from 0.40 (preferring HDT) to 1.10 (preferring SDT). Hazard estimates for PFS ranged from 0.42 to 1.69. The Q statistic showed significant heterogeneity: $p=0.002$ for OS and $p<0.001$ for PFS. No significant heterogeneity was present in the subgroup analyses of OS when only trials with ‘standard protocol’ or with ‘long follow-up’ were considered. With regard to PFS, only the subgroup of trials with ‘standard protocol’ showed no significant heterogeneity. The funnel plot gave no indication of publication bias.

**Combined HRs for OS with HDT.** The combined HR for OS gained from the nine trials was 0.90 (95% CI=0.74-1.10). There was no statistically significant OS benefit with HDT. The same result applied to the subgroups ‘no TBI’ (HR=0.84; 95% CI=0.50-1.39) and ‘long follow-up’ (HR=1.06; 95% CI=0.94-1.20). The subgroup ‘standard protocols’ showed a trend for an OS benefit with HDT (HR=0.87; 95% CI=0.74-1.02). Removing every single trial from the analysis in turn did not lead to relevant differences in the effects (not illustrated). Results are illustrated in Figure 1.

**Combined HRs for PFS with HDT.** The publications of the nine trials gave information on PFS or event-free-survival. As the definition of both terms is similar, the results were summarized as PFS. The combined HR for the nine studies was 0.73 (95%
The PFS benefit with HDT was significant (\(p=0.018\)). While the same result was observed for the subgroup analysis of ‘standard protocols’, HR=0.76 (95% CI=0.67-0.87), \(p<0.001\), the analysis both of ‘no TBI’ and of ‘long follow-up’ provided no benefit in PFS for HDT, with HRs of 0.81 (95% CI=0.48-1.35), 0.81 (95% CI=0.57-1.16) respectively. Removing every single trial from the analysis reduced the PFS benefit to only a trend in two cases (\(p=0.055\) and \(p=0.056\)), while the effect remained significant in seven cases (not illustrated). Results are illustrated in Figure 2.

### Conclusion

Although myeloablative chemotherapy with stem cell support is considered standard therapy for patients younger than 65 years with no other limitations, its effect on OS for these patients remains under discussion. Therefore, Koreth et al. (10) undertook a systematic review to identify all RCTs that addressed that question. In their meta-analysis of nine qualified trials, they found a significant benefit in PFS but not in OS. As new data were available on two trials, we repeated the meta-analysis to further clarify the role of HDT in myeloma. With relation to all nine trials, there was no statistically significant OS benefit with HDT, which is currently still regarded as the first-line treatment. In the subgroup of ‘standard protocols’ we found a trend for an OS benefit with HDT. The results do still speak rather in favor of than against the actual practice guidelines as other options such as tandem or allogenic transplantation have not led to an increased OS benefit (22, 23). Whereas the introduction of novel agents has provided a large benefit for patients with MM, it has not yet been satisfactorily evaluated whether use of novel agents is more beneficial in standard chemotherapy or in myeloablative application. Of course one problem of the interpretation of the data is the heterogeneity of the included trials, especially of the newer ones focused on patients that were only eligible for a dose-reduced myeloablative regimen. This is due to the fact that HDT has been standard therapy for many years now. Therefore, the subgroup analysis excluding these ‘non-standard’ trials was performed. It did not result in significantly different effects but did show a trend for improved OS for HDT. Currently conducted RCTs focus on treatment of patients with relapse (phase III: NCT00083876, www.clinicaltrials.gov) or of patients ineligible for

<table>
<thead>
<tr>
<th>Study (Author)</th>
<th>Entry criteria</th>
<th>Response rate (CR)</th>
<th>TRM</th>
<th>Results: Salvage HDT</th>
<th>PFS/EFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFM 90 (Attal)</td>
<td>Untreated MM, DSS II or III, no chemo- or radiotherapy, no cardiac, pulmonary or hepatic dysfunction, no psychiatric disease</td>
<td>0.05</td>
<td>0.22</td>
<td>NR</td>
<td>0.02</td>
</tr>
<tr>
<td>MAG 90 (Fermand)</td>
<td>Symptomatic MM, &lt;56 years, no prior chemo- or radiotherapy, no renal, cardiac, hepatic or pulmonary dysfunction</td>
<td>0.05</td>
<td>0.19</td>
<td>0.14</td>
<td>0.1</td>
</tr>
<tr>
<td>MAG 91 (Fermand)</td>
<td>Untreated symptomatic MM, no chemo- or radiotherapy, no renal, cardiac, hepatic or pulmonary dysfunction</td>
<td>0.04</td>
<td>0.06</td>
<td>0.02</td>
<td>0.05</td>
</tr>
<tr>
<td>MRC7 (Child) (Barlogie)</td>
<td>Untreated MM, &lt;65 years, met MRC criteria, suitable for HDT</td>
<td>0.08</td>
<td>0.44</td>
<td>NR</td>
<td>0.03</td>
</tr>
<tr>
<td>S9321 (Bladé)</td>
<td>Untreated symptomatic MM, &lt;70 years, Zubrod performance status 0-2; no cardiac or pulmonary dysfunction, no other malignancy within the last 5 years</td>
<td>0.05</td>
<td>0.07</td>
<td>&lt;1%</td>
<td>0.03</td>
</tr>
<tr>
<td>PETHEMA (Bladé)</td>
<td>Newly diagnosed untreated MM, &lt;70 years, symptomatic DSS II or III, PS 0 to 2</td>
<td>0.11</td>
<td>0.3</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>HOVON 24 (Sonneveld)</td>
<td>Untreated MM, 18-65 years, DSS II+III, no other actual or prior malignant diseases (except non-melanoma skin tumors), cardiac, pulmonary, renal or organ dysfunction, inadequate liver function, no prior radiotherapy</td>
<td>0.13</td>
<td>0.32</td>
<td>0.04</td>
<td>0.1</td>
</tr>
<tr>
<td>M97G (Palumbo)</td>
<td>Untreated MM, 50 to 70 years, abnormal cardiac, hepatic or renal function; no HBV, HCVB or HIV, no other cancer or psychiatric disease</td>
<td>6%</td>
<td>25%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>IFM 99-06 (Facon)</td>
<td>Untreated MM, 65-75 years or ineligible for HDT for other reasons, DSS II+III or I (high risk), no other neoplasm (except basocellular epithelioma), no amyloidosis, creatinine &lt;50 mg/L, no cardiac or hepatic dysfunction, no infection (HIV, HepB or C)</td>
<td>2%</td>
<td>18%</td>
<td>2%</td>
<td>5%</td>
</tr>
</tbody>
</table>

CR: Complete remission; DS: Durie-Salmon stage; EFS: event-free survival; HDT: high-dose therapy; SDT: standard-dose therapy; M M: multiple myeloma; OS: overall survival; PFS: progression-free survival; TMR: treatment related mortality.
conventional HDT regimens (phase III: NCT00232934, www.clinicaltrials.gov) as did some of the studies included in this meta-analysis. Additional data from ongoing clinical trials and new studies using novel agents such as thalidomide, lenalidomide and bortezomib, also in standard regimens, are warranted to finally evaluate the role of HDT in the treatment management of patients with newly diagnosed MM.

Acknowledgements

This work is part of the medical thesis of Florian Faussner and was supported by Celgene, Munich, with a travel grant for presentation at the 52nd American Society of Hematology meeting.

Support in the performance of the meta-analysis provided by Dr. Markus Pfirrmann, Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig Maximilian University Munich, is gratefully acknowledged.

References


Figure 2. Forest plot of the progression free survival benefit of myeloablative chemotherapy with autologous stem cell transplantation (HDT) vs. nonmyeloablative chemotherapy (SDT). The position of a box represents the effect (confidence intervals (CI) are represented by the lines). The size of a box is proportional to the weight of the trial. Final summary effects for all studies and for subgroups are represented by diamonds. HR: Hazard ratio; N: number of participants; TBI: total body irradiation.


